We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
McKesson Banks on Distribution Business Amid Pricing Woes
Read MoreHide Full Article
On Aug 14, we issued an updated research report on San Francisco, CA-based McKesson Corporation (MCK - Free Report) , a health care services and information technology company. McKesson posted disappointing results in first-quarter fiscal 2018, wherein adjusted earnings and revenues missed the Zacks Consensus Estimate. The company currently has a Zacks Rank #3 (Hold).
The quarter saw strong performance by the Distribution Solutions segment. The segment is expected to keep up its performance in fiscal 2018 despite weak pricing trends and customer consolidation. To boost growth, the company recently acquired CoverMyMeds for approximately $1.1 billion.
Coming to guidance, the Distribution Solutions business revenue growth is expected to witness robust growth on a year-over-year basis. The upside is expected to be driven by market growth and acquisitions.McKesson expects GAAP earnings per diluted share of $7.10-$9.00 for the fiscal ending Mar 31, 2018. Adjusted earnings for the same period are expected in the range of $11.80-$12.50 per diluted share.
On the flipside, pricing pressure in the independent retail pharmacy channel is a headwind. McKesson entered fiscal 2018 with an assumption of branded inflation in the mid-single digits and its first quarter slightly surpassed expectations.
McKesson has been witnessing increased price competition in the independent retail pharmacy channel, which eventually resulted in reduced volumes. The company continues to see a competitive market for selling generic pharmaceuticals in the U.S. However, McKesson expects to overcome the independent pharmacy sell-side pricing impact by the end of second-quarter fiscal 2018.
Furthermore, cutthroat competition in the niche markets, currency headwinds and reimbursement issues remain challenges.
Stock Performance and Estimate Revision Trend
Over the last three months, McKesson has been trading above the broader industry. The company has gained 5.1%, comparing favorably with the broader industry’s return of just 4%. The current level is also higher than the S&P 500’s return of only 4.6% over the same time frame.
The estimate revision trend for McKesson has been unfavorable at the moment. For the current quarter, six analysts moved south compared to no movement in the opposite direction over the last two months. As a result, magnitude of full-year estimates fell 4.8% to $2.76 over the same time frame.
Key Picks
A few better-ranked stocks in the broader medical sector are Edwards Lifesciences Corporation (EW - Free Report) , Masimo Corporation (MASI - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) .
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. Notably, the stock has returned 2.7% over the last three months.
Masimo yielded a strong return of 26.6% year to date. The stock has a long-term expected earnings growth rate of 11.1%.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. Additionally, the stock represents an impressive one-year return of 39.6%.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
McKesson Banks on Distribution Business Amid Pricing Woes
On Aug 14, we issued an updated research report on San Francisco, CA-based McKesson Corporation (MCK - Free Report) , a health care services and information technology company. McKesson posted disappointing results in first-quarter fiscal 2018, wherein adjusted earnings and revenues missed the Zacks Consensus Estimate. The company currently has a Zacks Rank #3 (Hold).
The quarter saw strong performance by the Distribution Solutions segment. The segment is expected to keep up its performance in fiscal 2018 despite weak pricing trends and customer consolidation. To boost growth, the company recently acquired CoverMyMeds for approximately $1.1 billion.
Coming to guidance, the Distribution Solutions business revenue growth is expected to witness robust growth on a year-over-year basis. The upside is expected to be driven by market growth and acquisitions.McKesson expects GAAP earnings per diluted share of $7.10-$9.00 for the fiscal ending Mar 31, 2018. Adjusted earnings for the same period are expected in the range of $11.80-$12.50 per diluted share.
On the flipside, pricing pressure in the independent retail pharmacy channel is a headwind. McKesson entered fiscal 2018 with an assumption of branded inflation in the mid-single digits and its first quarter slightly surpassed expectations.
McKesson has been witnessing increased price competition in the independent retail pharmacy channel, which eventually resulted in reduced volumes. The company continues to see a competitive market for selling generic pharmaceuticals in the U.S. However, McKesson expects to overcome the independent pharmacy sell-side pricing impact by the end of second-quarter fiscal 2018.
Furthermore, cutthroat competition in the niche markets, currency headwinds and reimbursement issues remain challenges.
Stock Performance and Estimate Revision Trend
Over the last three months, McKesson has been trading above the broader industry. The company has gained 5.1%, comparing favorably with the broader industry’s return of just 4%. The current level is also higher than the S&P 500’s return of only 4.6% over the same time frame.
The estimate revision trend for McKesson has been unfavorable at the moment. For the current quarter, six analysts moved south compared to no movement in the opposite direction over the last two months. As a result, magnitude of full-year estimates fell 4.8% to $2.76 over the same time frame.
A few better-ranked stocks in the broader medical sector are Edwards Lifesciences Corporation (EW - Free Report) , Masimo Corporation (MASI - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) .
Notably, Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while IDEXX Laboratories and Masimo Corporation have a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. Notably, the stock has returned 2.7% over the last three months.
Masimo yielded a strong return of 26.6% year to date. The stock has a long-term expected earnings growth rate of 11.1%.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. Additionally, the stock represents an impressive one-year return of 39.6%.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>